MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z
  • U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson’s disease

    A. Metcalfe, S. Udow, H. Sharmarke, Z. Shirzadi, D. Long, S. Duff-Canning, C. Marras, A. Lang, B. MacIntosh, M. Masellis (Toronto, ON, Canada)

  • Ultrasonography-guided Botulinum Toxin Type-A Injection in Tremor. An open-label Study

    H. Shehata, N. Shalaby, M. Basheer, A. Elmazny, S. Eljaafary (Cairo, Egypt)

  • Understanding neural activation in semantic fluency in Parkinson’s disease with mild cognitive impairment

    J.H. Julia, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

  • Understanding the illness experience of people living with Parkinson’s disease: A mixed methods study

    JJ.Y.-Y. Kwok, M.M. AuYeung, H.Y.-L. Chan (Hong Kong, Hong Kong)

  • Understanding the role of LRRK2 in Indian population

    A. Kishore, M. Sturm, A. Sreelatha, S. Robert, S. Krishnan, M. Banerjee, O. Riess, P. Bauer, R. Kruger, T. Gasser, M. Sharma (Trivandrum, India)

  • Unusual facial synkinesia after Bell’s palsy: interactive Marin-Amat syndrome proven by surface electromyogram, successfully treated with low dose botulinum toxin A.

    H. Mori (Kurashiki, Japan)

  • Unusual MRI findings of the syndrome of acute bilateral basal ganglia lesions in diabetic uremia with hyperglycemia associated dyskinesia

    P.-Y. Chen, A. Gutfreund, K. Brockmann, I. Wurster, G. Eschweiler, F. Metzger, W. Maetzler, D. Berg (Taipei, Taiwan)

  • Update on the MDS-Sponsored Systematic Review On Clinical Rating Scales for Huntington’s Disease: motor, cognitive, functional ability and quality of life domains

    T. Mestre, C. Sampaio, C. Goetz, P. Martinez-Martin, G. Stebbins (Ottawa, ON, Canada)

  • UPDRS benefit from dual frequency DBS fields sculpted by intentionally overlapped interleaving

    Y. Fernandez, D. Caputo, D. Schneider, R. Dipaola, S. Danish, E. Hargreaves (New York, NY, USA)

  • UPDRS III score and RS latency can determine the possible neuromodulative role of STN DBS in Parkinson’s disease (PD) patients

    S. Szlufik, A. Przybyszewski, J. Dutkiewicz, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

  • Use of latent class analysis and growth mixture modeling to examine longitudinal neurocognitive trajectories in non-demented Parkinson’s disease

    L. Brennan, K. Devlin, D. Mechanic-Hamilton, J. Rick, S. Xie, L. Chahine, N. Dahodwala, A. Chen-Plotkin, J. Duda, J. Morley, R. Akhtar, J. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

  • Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment

    D. Weintraub, J. Norton, D. Fredericks, B. Coate, C. Andersson, C. Ballard (Philadelphia, PA, USA)

  • Use of the Neuropsychiatric Inventory to Characterize the Course of Neuropsychiatric Symptoms in Progressive Supranuclear Palsy

    M. Jecmenica Lukic, T. Pekmezovic, I. Petrovic, A. Tomic, M. Svetel, V. Kostic (Belgrade, Serbia)

  • Using an Objective Measure of Movement to Quantify Night Time Sleep

    P. Farzanehfar, P. Churchward, M. Horne (Parkville, Australia)

  • Using cognitive computing to identify compounds with antidyskinetic potential for Parkinson’s disease

    N. Visanji, A. Lacoste, S. Ezell, S. Spangler, E. Argentinis, J. Brotchie, A. Lang, T. Johnston (Toronto, ON, Canada)

  • Using eye tracking to identify pupil and saccade biomarkers of neurodegenerative disease

    D. Munoz, B. Coe, J. Huang, M. Smorenburg, D. Brien, S. Black, M. Borrie, D. Dowlatshahi, E. Finger, D. Grimes, M. Freedman, A. Lang, C. Marras, M. Masellis, R. Swartz, C. Tartaglia, L. Zinman, t. ONDRI Investigators (Kingston, ON, Canada)

  • Using measurements from wearable sensors for automatic scoring of Parkinson’s disease motor states

    I. Thomas, F. Bergquist, R. Constantinescu, D. Nyholm, M. Senek, M. Memedi (Falun, Sweden)

  • Using the power of a Network to accomplish a Countrywide Review of Acute Parkinson’s Disease management

    E. Peter, B. Mohamed, C. Thomas (Bridgend, United Kingdom)

  • Utility of ataxia gene panel testing in diagnosing inherited ataxia: evaluation of an Irish cohort

    P. Bogdanova-Mihaylova, R. Walsh, S. Murphy (Dublin 24,, Ireland)

  • Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism

    M. Salgado, D. Panebianco, J. Muller, A. Ortega, S. (Brooklyn, NY, USA)

  • Utility of susceptibility weighted imaging in the objective diagnosis of idiopathic Parkinson’s Disease: Is DaTscan necessary?

    R. Ellis, M. Radon, M. Bonello, M. Steiger (Liverpool, United Kingdom)

  • Utility of THK-5351 tau-PET for differential diagnosis in patients with hypokinetic-rigid syndromes.

    G. Rohrer, S. Schönecker, M. Brendel, J. Havla, G. Höglinger, S. Lindner, C. Zach, F. Vettermann, C. Prix, G. Nübling, P. Bartenstein, K. Furukawa, A. Ishiki, N. Okamura, K. Bötzel, A. Rominger, J. Levin (Munich, Germany)

Jump to:  View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley